Suddenly, Trait-Based Embryo Selection

A thorough survey of trait-based polygenic embryo selection as it suddenly went from disease-only to traits (height, IQ, eye color) in 2025. Maps the companies (Genomic Prediction, Orchid, Nucleus, the newly-de-stealthed Herasight), the science (polygenic scores need within-family validation or headline risk reductions overstate, per the Missing-Heritability confounding work), and the cost-benefit case (under stated assumptions — full parent-child altruism, low discount rate, already doing IVF — it's clearly worth it: a 12% absolute diabetes-risk cut implies not-getting-diabetes is worth $27k; Herasight's ~6 IQ points likely pays for itself in income). Handles the objections rigorously: efficacy/within-family validation; antagonistic pleiotropy (the sharp valedictorian thought experiment — if you'd celebrate a naturally-smart child despite a tiny anorexia-risk bump, you should accept it via selection; most disease correlations are neutral-to-positive anyway); cost/inequality (follows the cellphone/genome price-collapse path; governments should cover it); personhood; race (works best for white people given biobank data); and the burden of actually choosing. Details the Herasight-vs-Nucleus dispute (inflated scores, the Marlboro-attacking-Camel irony) with a flagged conflict of interest. Closes that it's a romantic but possibly soon-obsolete 'foothill' given AI, alongside the aesthetic case for having kids and using the technology himself.

Quality 75 · Excellent. Strong band, upper / low-Excellent. Comprehensive, fair, and genuinely useful survey of a fast-moving, controversial field, with real analytical contributions (the antagonistic-pleiotropy valedictorian argument, the disciplined cost-benefit framing) and a memorable closing. Held at the Strong/Excellent border by the heavy company-dispute content and a candidly-flagged conflict of interest (commissioned around Herasight's white paper; personal use/possible investment).

Claude’s paradigm shift 45 · Moderate. Moderate. Largely reports the state of an industry and applies standard cost-benefit and the prior heritability-confounding work; the pleiotropy framing is a fresh, sharp move rather than a new idea.

Real-world impact 3 · Moderate. A comprehensive, fair survey of trait-based polygenic embryo selection as it went mainstream in 2025 (the companies, the within-family-validation caveat, a disciplined cost-benefit case) — a real, emerging, materially-consequential biotechnology. Genuinely useful to families weighing it, but the post informs the debate rather than effecting change — modest RWI.